Literature DB >> 24104749

The regulatory landscape for actively personalized cancer immunotherapies.

Cedrik M Britten1, Harpreet Singh-Jasuja, Bruno Flamion, Axel Hoos, Christoph Huber, Karl-Josef Kallen, Samir N Khleif, Sebastian Kreiter, Michaela Nielsen, Hans-Georg Rammensee, Ugur Sahin, Thomas Hinz, Ulrich Kalinke.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24104749     DOI: 10.1038/nbt.2708

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  13 in total

1.  Immunotherapy at large: the road to personalized cancer vaccines.

Authors:  Robert H Vonderheide; Katherine L Nathanson
Journal:  Nat Med       Date:  2013-09       Impact factor: 53.440

2.  Individual genomes on the horizon.

Authors:  Richard P Lifton
Journal:  N Engl J Med       Date:  2010-03-10       Impact factor: 91.245

Review 3.  MHC ligands and peptide motifs: first listing.

Authors:  H G Rammensee; T Friede; S Stevanoviíc
Journal:  Immunogenetics       Date:  1995       Impact factor: 2.846

4.  Integrated functional genomics approach for the design of patient-individual antitumor vaccines.

Authors:  Toni Weinschenk; Cécile Gouttefangeas; Markus Schirle; Florian Obermayr; Steffen Walter; Oliver Schoor; Raffael Kurek; Wolfgang Loeser; Karl-Horst Bichler; Dorothee Wernet; Stefan Stevanović; Hans-Georg Rammensee
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

5.  The consensus coding sequences of human breast and colorectal cancers.

Authors:  Tobias Sjöblom; Siân Jones; Laura D Wood; D Williams Parsons; Jimmy Lin; Thomas D Barber; Diana Mandelker; Rebecca J Leary; Janine Ptak; Natalie Silliman; Steve Szabo; Phillip Buckhaults; Christopher Farrell; Paul Meeh; Sanford D Markowitz; Joseph Willis; Dawn Dawson; James K V Willson; Adi F Gazdar; James Hartigan; Leo Wu; Changsheng Liu; Giovanni Parmigiani; Ben Ho Park; Kurtis E Bachman; Nickolas Papadopoulos; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu
Journal:  Science       Date:  2006-09-07       Impact factor: 47.728

6.  Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome.

Authors:  David P Carbone; I Frank Ciernik; Michael J Kelley; M Charles Smith; Sorena Nadaf; Denise Kavanaugh; V Ellen Maher; Michael Stipanov; David Contois; Bruce E Johnson; C David Pendleton; Burkhardt Seifert; Charley Carter; Elizabeth J Read; Jay Greenblatt; Lois E Top; Morris I Kelsey; John D Minna; Jay A Berzofsky
Journal:  J Clin Oncol       Date:  2005-06-27       Impact factor: 44.544

7.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing.

Authors:  Marco Gerlinger; Andrew J Rowan; Stuart Horswell; James Larkin; David Endesfelder; Eva Gronroos; Pierre Martinez; Nicholas Matthews; Aengus Stewart; Charles Swanton; M Math; Patrick Tarpey; Ignacio Varela; Benjamin Phillimore; Sharmin Begum; Neil Q McDonald; Adam Butler; David Jones; Keiran Raine; Calli Latimer; Claudio R Santos; Mahrokh Nohadani; Aron C Eklund; Bradley Spencer-Dene; Graham Clark; Lisa Pickering; Gordon Stamp; Martin Gore; Zoltan Szallasi; Julian Downward; P Andrew Futreal
Journal:  N Engl J Med       Date:  2012-03-08       Impact factor: 91.245

8.  Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting.

Authors:  Hirokazu Matsushita; Matthew D Vesely; Daniel C Koboldt; Charles G Rickert; Ravindra Uppaluri; Vincent J Magrini; Cora D Arthur; J Michael White; Yee-Shiuan Chen; Lauren K Shea; Jasreet Hundal; Michael C Wendl; Ryan Demeter; Todd Wylie; James P Allison; Mark J Smyth; Lloyd J Old; Elaine R Mardis; Robert D Schreiber
Journal:  Nature       Date:  2012-02-08       Impact factor: 49.962

9.  A pilot clinical trial testing mutant von Hippel-Lindau peptide as a novel immune therapy in metastatic renal cell carcinoma.

Authors:  Osama E Rahma; Ed Ashtar; Ramy Ibrahim; Antoun Toubaji; Barry Gause; Vincent E Herrin; W Marston Linehan; Seth M Steinberg; Frank Grollman; George Grimes; Sarah A Bernstein; Jay A Berzofsky; Samir N Khleif
Journal:  J Transl Med       Date:  2010-01-28       Impact factor: 5.531

10.  Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells.

Authors:  Paul F Robbins; Yong-Chen Lu; Mona El-Gamil; Yong F Li; Colin Gross; Jared Gartner; Jimmy C Lin; Jamie K Teer; Paul Cliften; Eric Tycksen; Yardena Samuels; Steven A Rosenberg
Journal:  Nat Med       Date:  2013-05-05       Impact factor: 53.440

View more
  22 in total

1.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

Review 2.  Mapping the tumour human leukocyte antigen (HLA) ligandome by mass spectrometry.

Authors:  Lena Katharina Freudenmann; Ana Marcu; Stefan Stevanović
Journal:  Immunology       Date:  2018-05-08       Impact factor: 7.397

Review 3.  mRNA-based therapeutics--developing a new class of drugs.

Authors:  Ugur Sahin; Katalin Karikó; Özlem Türeci
Journal:  Nat Rev Drug Discov       Date:  2014-09-19       Impact factor: 84.694

Review 4.  Victory and defeat in the induction of a therapeutic response through vaccine therapy for human and canine brain tumors: a review of the state of the art.

Authors:  Michael R Olin; G Elizabeth Pluhar; Brian M Andersen; Rob Shaver; Nate N Waldron; Christopher L Moertel
Journal:  Crit Rev Immunol       Date:  2014       Impact factor: 2.214

Review 5.  Vaccine-based immunotherapeutic approaches to gliomas and beyond.

Authors:  Michael Weller; Patrick Roth; Matthias Preusser; Wolfgang Wick; David A Reardon; Michael Platten; John H Sampson
Journal:  Nat Rev Neurol       Date:  2017-05-12       Impact factor: 42.937

6.  Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations.

Authors:  Axel Hoos
Journal:  Nat Rev Drug Discov       Date:  2016-03-11       Impact factor: 84.694

Review 7.  Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers.

Authors:  Vanessa Acebes-Fernández; Alicia Landeria-Viñuela; Pablo Juanes-Velasco; Angela-Patricia Hernández; Andrea Otazo-Perez; Raúl Manzano-Román; Rafael Gongora; Manuel Fuentes
Journal:  Nanomaterials (Basel)       Date:  2020-06-29       Impact factor: 5.076

8.  High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma.

Authors:  Carsten Linnemann; Marit M van Buuren; Laura Bies; Els M E Verdegaal; Remko Schotte; Jorg J A Calis; Sam Behjati; Arno Velds; Henk Hilkmann; Dris El Atmioui; Marten Visser; Michael R Stratton; John B A G Haanen; Hergen Spits; Sjoerd H van der Burg; Ton N M Schumacher
Journal:  Nat Med       Date:  2014-12-22       Impact factor: 53.440

Review 9.  Identification of neoantigens for individualized therapeutic cancer vaccines.

Authors:  Franziska Lang; Barbara Schrörs; Martin Löwer; Özlem Türeci; Ugur Sahin
Journal:  Nat Rev Drug Discov       Date:  2022-02-01       Impact factor: 112.288

Review 10.  Methods for improving the immunogenicity and efficacy of cancer vaccines.

Authors:  Lorenzo Pilla; Soldano Ferrone; Cristina Maccalli
Journal:  Expert Opin Biol Ther       Date:  2018-06-17       Impact factor: 4.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.